LRRC25 Inhibitors
LRRC25 inhibitors constitute a diverse array of chemical compounds that target various cellular signaling pathways, indirectly leading to the inhibition of LRRC25 function. These inhibitors are not selective for LRRC25 but act on upstream regulators or processes that modulate the activity of LRRC25 within the cell. For instance, Bisindolylmaleimide I functions as a kinase inhibitor that dampens the phosphorylation state of proteins within signaling cascades that LRRC25 potentially regulates or is regulated by. This results in the attenuation of LRRC25-related signaling outcomes. Similarly, LY294002 and Wortmannin act as potent PI3K inhibitors, preventing the initiation of the PI3K/AKT pathway, which is critical for a multitude of cellular processes. By blocking this pathway, these inhibitors indirectly decrease the functional activity of LRRC25, which may be contingent upon PI3K/AKT signaling for its proper role within the cellular environment.
Compounds such as U0126 and PD98059 are specific to the MAPK/ERK pathway, another major signaling conduit that can affect a broad spectrum of proteins including LRRC25. Inhibition of MEK, which is an essential component of this pathway, results in diminished ERK activation and potentially lowers the functional influence of LRRC25.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
A protein kinase C inhibitor that decreases the phosphorylation of various proteins, which may include substrates involved in the signaling pathways where LRRC25 has a regulatory role. Inhibition of these pathways can lead to reduced LRRC25-mediated signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A phosphoinositide 3-kinase (PI3K) inhibitor that prevents the PI3K/AKT pathway activation. Since LRRC25 activity can be modulated by changes in this pathway, LY294002 can indirectly lead to the diminished function of LRRC25 by preventing pathway activation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor that blocks the p38 MAPK pathway activity. LRRC25 functionality might be influenced by the modulation of downstream targets of p38 MAPK, hence its inhibition could result in reduced LRRC25 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Another PI3K inhibitor that impedes the PI3K/AKT pathway. By inhibiting this pathway, the activity of proteins potentially regulated by PI3K/AKT such as LRRC25 can be indirectly diminished. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that inhibits the mTORC1 complex, which might regulate proteins involved in LRRC25-related signaling events. Inhibition of this complex can result in decreased LRRC25 function. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
A ROCK inhibitor that interferes with the RhoA/ROCK pathway. Since the RhoA/ROCK pathway can regulate a variety of cellular functions, inhibition by Y-27632 can lead to the downregulation of LRRC25 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A specific inhibitor of MEK that prevents the activation of the MAPK/ERK pathway. As LRRC25 might be affected by this pathway, PD98059 can indirectly cause reduced LRRC25 function by blocking pathway activation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK that impedes JNK signaling. As LRRC25 may interact with pathways involving JNK, inhibition by SP600125 can lead to decreased LRRC25 activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
A Src family kinase inhibitor that can suppress signaling pathways involving Src kinases. As these kinases can influence the activity of proteins like LRRC25, PP2 can lead to reduced LRRC25 function. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
An inhibitor of NF-κB activation that can suppress the NF-κB pathway. Since LRRC25 might be involved in NF-κB-related signaling, BAY 11-7082 can indirectly decrease LRRC25 activity by preventing NF-κB activation. | ||||||